Pages that link to "Item:Q746098"
From MaRDI portal
The following pages link to Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity (Q746098):
Displaying 10 items.
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- A Bayesian dose-finding design for drug combination trials with delayed toxicities (Q908029) (← links)
- Evaluation of treatment effect with paired failure times in a single-arm phase II trial in oncology (Q1731291) (← links)
- A Bayesian phase I/II clinical trial design in the presence of informative dropouts (Q1747447) (← links)
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials (Q2059113) (← links)
- Adaptive Decision Making in a Lymphocyte Infusion Trial (Q3078989) (← links)
- Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes (Q3183237) (← links)
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology (Q5866135) (← links)
- A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial (Q6074511) (← links)
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
